Johnson & Johnson showcases latest advancements in Alzheimer's research at AAIC 2025
Johnson & Johnson (NYSE:JNJ) will present significant advancements in Alzheimer's disease research at the Alzheimer's Association International Conference (AAIC) from July 27-31, 2025, in Toronto. The company will showcase 12 research abstracts focusing on tau's impact on brain function in early Alzheimer's and the predictive capabilities of plasma biomarker pTau217.
A key highlight includes new findings from the Global Neurodegeneration Proteomics Consortium (GNPC), a partnership between J&J and Gates Ventures, representing the world's largest neurodegenerative disease proteomics resource. The research spans various areas, including tau PET imaging, CSF proteomics, plasma biomarkers, and AI-based diagnostic approaches.
Johnson & Johnson (NYSE:JNJ) presenterà importanti progressi nella ricerca sull'Alzheimer durante il Convegno Internazionale dell'Alzheimer Association (AAIC), che si terrà dal 27 al 31 luglio 2025 a Toronto. L'azienda esporrà 12 abstract di ricerca focalizzati sull'impatto della proteina tau sulla funzione cerebrale nelle fasi iniziali dell'Alzheimer e sulle capacità predittive del biomarcatore plasmatico pTau217.
Un punto saliente riguarda i nuovi risultati del Global Neurodegeneration Proteomics Consortium (GNPC), una collaborazione tra J&J e Gates Ventures, che rappresenta la più grande risorsa mondiale di proteomica per le malattie neurodegenerative. La ricerca copre diversi ambiti, tra cui l'imaging tau PET, la proteomica del liquido cerebrospinale, i biomarcatori plasmatici e gli approcci diagnostici basati sull'intelligenza artificiale.
Johnson & Johnson (NYSE:JNJ) presentará avances significativos en la investigación del Alzheimer en la Conferencia Internacional de la Asociación de Alzheimer (AAIC), que se celebrará del 27 al 31 de julio de 2025 en Toronto. La compañía mostrará 12 resúmenes de investigación centrados en el impacto de la proteína tau en la función cerebral en las primeras etapas del Alzheimer y en la capacidad predictiva del biomarcador plasmático pTau217.
Un aspecto destacado incluye nuevos hallazgos del Consorcio Global de Proteómica de Neurodegeneración (GNPC), una colaboración entre J&J y Gates Ventures, que representa el recurso proteómico más grande del mundo para enfermedades neurodegenerativas. La investigación abarca varias áreas, incluyendo la imagen PET de tau, la proteómica del líquido cefalorraquídeo, biomarcadores plasmáticos y enfoques diagnósticos basados en inteligencia artificial.
Johnson & Johnson (NYSE:JNJ)는 2025년 7월 27일부터 31일까지 토론토에서 열리는 알츠하이머 협회 국제 학술대회(AAIC)에서 알츠하이머병 연구의 중요한 진전을 발표할 예정입니다. 회사는 초기 알츠하이머에서 뇌 기능에 대한 타우 단백질의 영향과 혈장 바이오마커 pTau217의 예측 능력에 초점을 맞춘 12개의 연구 초록을 선보일 것입니다.
주요 하이라이트로는 J&J와 Gates Ventures가 협력하는 세계 최대 신경퇴행성 질환 프로테오믹스 자원인 글로벌 신경퇴행성 프로테오믹스 컨소시엄(GNPC)의 새로운 연구 결과가 포함됩니다. 연구는 타우 PET 영상, 뇌척수액 프로테오믹스, 혈장 바이오마커, AI 기반 진단 접근법 등 다양한 분야를 아우릅니다.
Johnson & Johnson (NYSE:JNJ) présentera des avancées majeures dans la recherche sur la maladie d'Alzheimer lors de la Conférence Internationale de l'Association Alzheimer (AAIC) qui se tiendra du 27 au 31 juillet 2025 à Toronto. L'entreprise mettra en avant 12 résumés de recherche portant sur l'impact de la protéine tau sur la fonction cérébrale dans les premiers stades de la maladie d'Alzheimer ainsi que sur les capacités prédictives du biomarqueur plasmatique pTau217.
Un point fort inclut de nouvelles découvertes du Global Neurodegeneration Proteomics Consortium (GNPC), un partenariat entre J&J et Gates Ventures, représentant la plus grande ressource mondiale en protéomique des maladies neurodégénératives. Les recherches couvrent divers domaines, notamment l'imagerie tau par PET, la protéomique du liquide céphalorachidien, les biomarqueurs plasmatiques et les approches diagnostiques basées sur l'intelligence artificielle.
Johnson & Johnson (NYSE:JNJ) wird bedeutende Fortschritte in der Alzheimer-Forschung auf der Alzheimer's Association International Conference (AAIC) vom 27. bis 31. Juli 2025 in Toronto vorstellen. Das Unternehmen präsentiert 12 Forschungsabstracts, die sich auf die Auswirkungen von Tau auf die Gehirnfunktion im frühen Stadium der Alzheimer-Krankheit und die prognostischen Fähigkeiten des Plasma-Biomarkers pTau217 konzentrieren.
Ein wichtiger Höhepunkt sind neue Erkenntnisse des Global Neurodegeneration Proteomics Consortium (GNPC), einer Partnerschaft zwischen J&J und Gates Ventures, die die weltweit größte proteomische Ressource für neurodegenerative Erkrankungen darstellt. Die Forschung erstreckt sich über verschiedene Bereiche, darunter Tau-PET-Bildgebung, Liquorproteomik, Plasma-Biomarker und KI-basierte Diagnoseverfahren.
- Partnership with Gates Ventures on GNPC demonstrates strong collaborative research initiatives
- Company's leadership position in Alzheimer's research and multimodal biomarkers
- Development of advanced diagnostic tools and biomarkers for early detection
- None.
Early data from robust Autonomy Phase 2b posdinemab trial demonstrate Company's leadership in multimodal biomarkers and early detection
New findings highlight the central role of tau in disease progression, bolstering confidence in the Company's industry-leading anti-tau portfolio
Featured research session to share new findings from GNPC, the world's largest neurodegenerative disease proteomics resource, co-founded with Gates Ventures
"Our long-standing leadership in Alzheimer's disease research gives us critical perspective on where the field has been and where it needs to go," said Bill Martin, Ph.D., Global Therapeutic Area Head, Neuroscience, Johnson & Johnson. "These data reflect how we are reconceptualizing the way we diagnose and treat disorders that are among the most prevalent and debilitating of our time, underscoring our unmatched legacy of advancing neuroscience and improving lives, and bringing us closer to a future where Alzheimer's disease may one day be a thing of the past."
Following the July 15 publication in Nature Medicine and Nature Aging, and the public release of the GNPC dataset, leaders from Johnson & Johnson and Gates Ventures will host a featured research session at AAIC to share new findings from the world's largest neurodegenerative disease proteomics resource.
"Long-standing challenges in assembling large, diverse datasets have made progress in understanding the biology of neurodegenerative diseases extremely slow. At AAIC, we are sharing how the GNPC is enabling discovery at scale," said Niranjan Bose, Ph.D., Managing Director, Health & Life Sciences at Gates Ventures. "Even at this early stage, researchers are uncovering new insights into some of the most studied risk factors, highlighting the power of the GNPC to drive discovery, reveal new targets, and ultimately accelerate progress for the more than 57 million people living with Alzheimer's disease and other dementias worldwide."
The following Company-sponsored and Company-partnered abstracts will be presented at AAIC 2025:
Abstract | Title | Date | Time |
#106362 | External validation of joint propagation model-based | July 27 | 7:30 AM – 4:15 PM |
#102872 | Increasing precision beyond A/T/N: Identification of | July 27 | 7:30 AM – 4:15 PM |
#105163 | Cortical free water correlates with tau phosphorylation | July 27 | 7:30 AM – 4:15 PM |
#106366 | Plasma biomarkers predict long-term longitudinal | July 28 | 7:30 AM – 4:15 PM |
#108563 | Microglial proteomic signature in human CSF allows | July 28 | 7:30 AM – 4:15 PM |
#100821 | Assessment of association of tau PET spatial patterns | July 28 | 7:30 AM – 4:15 PM
|
#100107 | Analysis of reasons for screen failure by participant | July 28 | 7:30 AM – 4:15 PM |
#102581 | Effect of amyloid, tau and syndromic stages of | July 28
| 7:30 AM – 4:15 PM
|
#100281 | Plasma protein signature as easily accessible | July 29 | 7:30 AM – 4:15 PM |
#99623 | Integrative multi-omics analysis reveals physiological | July 30 | 9:00 AM – 9:15 AM
|
#99373 | Benchmarking the AI-based diagnostic potential of | July 30 | 4:30 – 4:45 PM EDT |
#106046
| Plasma biomarkers move at different rates across the
| N/A | N/A |
ABOUT ALZHEIMER'S DISEASE (AD) & DEMENTIA
Alzheimer's disease (AD), the most common form of dementia worldwide, is a fatal neurodegenerative disorder characterized by progressive memory loss and a decline in other cognitive abilities severe enough to significantly interfere with daily life.1 Diagnostic criteria for AD are based on established classifications but continue to evolve as research advances. Preclinical AD refers to individuals with detectable AD pathology (amyloid and tau) who are cognitively unimpaired. Early AD includes individuals with mild cognitive impairment due to AD (also known as prodromal AD) and mild Alzheimer's dementia.
As AD advances, patients experience worsening cognitive decline, eventually losing the ability to perform basic tasks, communicate or recognize loved ones, ultimately leading to death.1 There is no cure for AD, and despite several new advancements, significant unmet need remains across the spectrum of this devastating disease.
ABOUT POSDINEMAB
Posdinemab is an investigational monoclonal antibody that is designed to target the mid-domain of AD-specific phosphorylated tau. Posdinemab is designed to bind to pathological phosphorylated tau when it is released from neurons and neutralize it before it can seed/spread to another neuron. The internally-discovered antibody has shown promise in reducing tau seeding—the process by which toxic tau spreads through the brain—in both in vitro and in vivo non-clinical studies.
The Phase 2b "AuTonomy" study investigating posdinemab in participants with early AD is fully enrolled and ongoing (NCT04619420).
ABOUT JOHNSON & JOHNSON
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and where solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Learn more at https://www.jnj.com/ or at https://innovativemedicine.jnj.com/
Follow us at @JNJInnovMed.
Janssen Research & Development, LLC is a Johnson & Johnson company.
CAUTIONS CONCERNING FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of posdinemab. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products, and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of healthcare products and services; changes to applicable laws and regulations, including global healthcare reforms; and trends toward healthcare cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
© Johnson & Johnson 2025. All rights reserved.
Media contact:
Allie Prull
Johnson & Johnson
aprull2@its.jnj.com
Investor contact:
Lauren Johnson
Johnson & Johnson
investor-relations@its.jnj.com
1. Alzheimer's Association. 2025 Alzheimer's Disease Facts and Figures. Accessed June 2025. https://www.alz.org/media/documents/alzheimers-facts-and-figures.pdf |
View original content to download multimedia:https://www.prnewswire.com/news-releases/johnson--johnson-showcases-latest-advancements-in-alzheimers-research-at-aaic-2025-302512531.html
SOURCE Johnson & Johnson
FAQ
What will Johnson & Johnson (JNJ) present at AAIC 2025?
What is the Global Neurodegeneration Proteomics Consortium (GNPC) announced by Johnson & Johnson?
When and where will Johnson & Johnson present at AAIC 2025?
What are the key research areas in JNJ's AAIC 2025 presentations?
